Our Firm is representing clients in this proceeding, and this Order will allow plaintiffs to present information that may prove relevant to their claims.
New York, NY (PRWEB) May 14, 2015
Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) filed on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin continue to move forward in the multidistrict litigation underway in U.S. District Court, District of South Carolina. According to an Order dated May 4th, the Court will allow Plaintiffs to serve supplemental reports for two of their expert witnesses. In addition, the Court has amended its scheduling order to allow time for Pfizer, Inc. to conduct full discovery on these new reports. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is representing clients in this proceeding, and this Order will allow plaintiffs to present information that may prove relevant to their claims. We are pleased to see that discovery is moving forward in this proceeding,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing numerous victims of defective medical devices and drugs including Lipitor. The Firm continues to offer free and confidential Lipitor lawsuit evaluations to individuals who developed diabetes after use of this cholesterol statin.
Court records indicate that Lipitor lawsuit filings began to mount after the U.S. Food & Drug Administration (FDA) announced in February 2012 that all statin labels would be updated to include information about their potentially harmful effects on blood glucose levels. The multidistrict litigation underway in South Carolina was established in February 2014, to allow all federally-filed Lipitor lawsuits involving diabetes allegations to undergo coordinated pretrial proceedings. Since then, more than 2,200 cases have been filed in the multidistrict litigation.
According to court documents, all of the Lipitor lawsuits pending in South Carolina accuse Pfizer of failing to warn that use of its statin medication could increase the risk that a patient will develop Type 2 diabetes. Plaintiffs further allege that the information added to the Lipitor label following the FDA’s 2012 mandate does not sufficiently warn patients about the association between Lipitor and diabetes.
Lipitor patients who allegedly developed Type 2 diabetes due to its use may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages related to the disorder. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have ben able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com